Search This Blog

Saturday, February 12, 2022

'Not Going To Happen To Me Again' - Prepping Goes Mainstream In Post-COVID Era

 Consumer psychology radically changed during the early days of the virus pandemic as shortages at supermarkets emerged. Bulk-buying habits were never a thing with the modern consumer in a pre-COVID world, but now 'prepping' has gone mainstream two years since the beginning of the virus pandemic as supply chains remain snarled and food inflation is out-of-control. Many have discovered: be prepared or be hungry. 

The pandemic was an eye-opener for tens of millions of consumers who learned the government and big corporations wouldn't take care of them when things go south. Even our elected officials were nowhere to be found in the early days of the pandemic when people panic hoarded food at supermarkets and fought over toilet paper in a 'free for all battle royale'. 

WSJ interviewed consumers across the country who've expressed their purchasing habits have changed. 

"Bulk-buying habit is expected to stick as people eat more at home, supply remains uncertain and inflation rears up. Retailers and producers are shifting operations as a result," WSJ said. 

Alexis Abell, a 41yo mother of five, buys in bulk out of fear of economic uncertainty. 

"I don't want to be in a position again where I can't get something," Abell said, who was laid off in 2020 and decided not to return to work. Her household spends about 25% more a week on food and staples versus a couple of years ago. 

"The stimulus money is gone, but we've gotten used to having more on hand and I'm cooking more at home, so I expect this to continue," she said. 

Many people expanded their pantries during the pandemic, bought freezers, and made space for non-perishables. WSJ calls "bulk shopping" "hoarding," though it's not and instead should be considered a form of prepping. 

Bob Nolan, senior vice president of Demand Science at food giant Conagra Brands Inc, has said consumers have "made permanent changes" after they experienced the "harsh realities of pandemic shortages." 

"They didn't just stock up that week, but they said to themselves, even if subconsciously, 'That's not going to happen to me again,'" Nolan said. 

Research firm IRI, which tracks consumption of household goods, confirms households are transforming into preppers as their average annual growth in sales by volume of food and beverages was 3% in 2020 and 2021, compared with just 0.5% average yearly growth for that last decade. IRI said consumers want larger package sizes. 

"Even if somebody waves a magic wand and makes Covid go away completely, we still expect elevated consumption in the home because people are accustomed to working from home, and hybrid work is here to stay," said Krishnakumar Davey, president of client engagement at IRI.

It's human nature to be prepared. Take, for instance, the "Silent Generation" and "Boomers" who either lived through the 1930s Great Depression or were raised by parents from that period learned to keep a large pantry of food and save almost everything they had due to socio-economic uncertainties. Scarcity is terrifying and can easily sway an entire generation of folks, such as "Millennials" and "Generation Z," who were accustomed to an on-demand society that abruptly came to a halt during the pandemic. Younger consumers were forever changed as their thoughts, beliefs, feelings, and perceptions of the economy changed during the pandemic. Thus what we're observing today is that consumers are becoming preppers.

Megan Crozier, Sam's chief merchant, said most new Sam's Club memberships in the third quarter of 2021 had been millennial households.  

Another variable pushing younger households into prepping is the hottest consumer prices in four decades. Consumers have noticed prices are going higher and higher for some foods every week. Global food prices are at a decade high and could easily reach a new high as early as this spring. People are stocking up on food because the product could either be unavailable next week or cost 20% more. 

Prepping is become mainstream and not as much "fringe" as it was perceived just a few years ago. This is a symptom of people losing trust in government and corporations. The evolution of thought for consumers is to break away from the matrix, buy land in a rural community with a decent internet connection and grow food and hunt. 

https://www.zerohedge.com/markets/not-going-happened-me-again-prepping-goes-mainstream-post-covid-era

Queen faces days of Covid testing

 Will be 'closely monitored' by Palace doctors after officials REFUSED to say if she has virus following meeting with Prince Charles two days before he was positive

  • Clarence House has confirmed Charles has tested positive for coronavirus and is now self-isolating
  • This is the second time the Prince of Wales has tested positive for Covid-19 after contracting it in March 2020
  • Prince met with the Queen on Tuesday - the same day he also hosted investiture ceremony at Windsor
  • Sources refused to confirm whether the Queen tested negative but she is not showing symptoms
  • The news comes hours after Charles attended black tie event with Priti Patel and Rishi Sunak

The Queen faces being tested for Covid for several days after it was revealed that she met Prince Charles just two days before he tested positive for the virus.

Buckingham Palace last night refused to confirm whether the 95-year-old monarch had tested positive or negative for Covid, fuelling fears for her health. However, palace sources insisted that she was not displaying symptoms.

Royal doctors will now test Her Majesty frequently after she saw her son the Prince of Wales at Windsor Castle on Tuesday, it is understood.

The Queen is understood to be triple vaccinated so will not need to self-isolate unless she tests positive. The head of state is thought to have received her first jab in January 2021 and her second jab that March, while sources say it is believed she got her booster in October.

This is the second time Charles, who is also triple jabbed, has tested positive for coronavirus after contracting the disease in March 2020.

Insiders insisted the 73-year-old was found to be positive during a test taken this morning as routine before any public engagements — which suggested he was experiencing no strong symptoms — but they declined to go into further details on his medical condition.

Both he and the Duchess of Cornwall have been taking regular tests before engagements and Clarence House said Camilla, 74, had a negative test on Thursday.

Under current Covid rules, although she lives with Charles, Camilla is not required to self-isolate as she is also fully vaccinated. While in the past, Covid rules would have dictated that all those who had come into contact with Charles must self-isolate, it is no longer a requirement.

Boris Johnson announced he plans to scrap all remaining virus restrictions in England by the end of the month, which would mean even those who have tested positive for the virus will not be required to self-isolate, ‘provided the current encouraging trends in the data continue’.

Downing Street said the Prime Minister hopes the Prince of Wales will make a swift recovery after testing positive.

As well as meeting with his mother, Charles also awarded OBEs to chefs Fergus Henderson, who has Parkinson’s Disease, and his wife Margot as well as an MBE to Dr Nisreen Alwan, who is known for campaigning for more awareness around long Covid.

The Queen, 95, does not have symptoms and the situation is being monitored. Pictured: The Queen on Monday

The news comes hours after Prince Charles (pictured, left, with Camilla)  attended a British Asian Trust event being hosted at the British Museum last night, Wednesday, February 9. He also hosted investitures on Tuesday where he met chefs and married couple Margot and Fergus Henderson, who has Parkinsons, are made OBEs by Prince Charles on Tuesday
The news comes hours after Prince Charles (pictured, left, with Camilla)  attended a British Asian Trust event being hosted at the British Museum last night, Wednesday, February 9. He also hosted investitures on Tuesday where he met chefs and married couple Margot and Fergus Henderson, who has Parkinsons, are made OBEs by Prince Charles on Tuesday

The news comes hours after Prince Charles (pictured, left, with Camilla)  attended a British Asian Trust event being hosted at the British Museum last night, Wednesday, February 9. He also hosted investitures on Tuesday where he met chefs and married couple Margot and Fergus Henderson, who has Parkinsons, are made OBEs by Prince Charles on Tuesday

Pictured: The Prince of Wales speaks to Home Secretary Priti Patel at an event to celebrate the British Asian Trust last night

Pictured: The Prince of Wales speaks to Home Secretary Priti Patel at an event to celebrate the British Asian Trust last night

The Prince of Wales has tested positive for Covid-19 and is self-isolating, Clarence House said. The news came hours after Charles gave a speech at a British Asian Trust event attended by Home Secretary Priti Patel and Chancellor Rishi Sunak

The Prince of Wales has tested positive for Covid-19 and is self-isolating, Clarence House said. The news came hours after Charles gave a speech at a British Asian Trust event attended by Home Secretary Priti Patel and Chancellor Rishi Sunak

https://www.dailymail.co.uk/news/article-10498195/Prince-Charles-tests-positive-Covid-forced-self-isolation.html

Engineered antibody helps block SARS-CoV-2 transmission

 Researchers at UC Davis Health have engineered a novel antibody, FuG1, that can directly interfere with the cell-to-cell transmission ability of SARS-CoV-2, the virus that causes COVID-19.

FuG1 targets the enzyme furin, which the  uses for its efficient chain of infections in human cells. The approach could be added to existing SARS-CoV-2 antibody cocktails for greater function against emerging variants.

A study evaluating the efficacy of the engineered antibody was published today in Microbiology Spectrum.

"We developed an approach that interferes with the transmission chain of SARS-CoV-2. The COVID-19 vaccines are a great lifesaver in reducing hospitalizations and severe illness. Yet, we are now learning that they may not be as effective in controlling the transmissibility of the virus," said Jogender Tushir-Singh, senior author of the study.

Tushir-Singh is an associate professor in the Department of Medical Microbiology and Immunology and a member of the UC Davis Comprehensive Cancer Center therapeutics program. His research uses rational protein engineering to generate multi-targeting  as cancer therapeutics. When the pandemic hit, he began thinking of similar strategies that might work to limit the spread of the coronavirus.

Enzyme activates SARS-CoV-2 spike protein

Furin, found throughout the human body, is involved in various functions of cells. It is a type of enzyme, a protease, that can break down proteins into smaller components. It does this by cutting, or cleaving, the polybasic peptide bonds within the proteins.

In cleaving these bonds, furin often acts as a switch, changing an inactive protein into an active one. For example, furin cleaves the inactive proparathyroid hormone into parathyroid hormone, which regulates calcium levels in the blood.

It can also cleave and activate viruses that enter . Pathogens that utilize furin in their  include HIV, influenza, dengue fever and SARS-CoV-2.

When SARS-CoV-2 infects a human cell, it is in its active state, having already "cleaved" its , a key protein that binds to ACE2 receptors to gain entry.

But when the virus is being synthesized within the host cell—when it is replicating—the  is in an inactive state. The virus needs to use the host cell's furin to cut the spike protein into two parts, S1 and S2, which makes the spike active on the viral particles for efficient transmissibility upon release.

"The virus exploits the host's furin to transmit from one cell to another and another. This added activation step is what makes the virus highly transmissible," said Tanmoy Mondal, the first author for the study and a post-doctoral researcher at UC Davis Health.

But inhibiting furin to limit the SARS-CoV-2 chain of infection cycle is not a straightforward mechanism.

"Furin is found throughout the  and is needed for the normal functioning of many biological processes. Stopping furin from doing its job causes high body toxicity. That is why the standard furin inhibitor drugs are not a clinically feasible option," Tushir-Singh said.

Instead, he and his team engineered a conjugated antibody targeting the SARS-CoV-2 spike protein. The design is similar to therapeutic monoclonal (IgG) antibodies but includes an added feature—Fc-extended peptide—that specifically interferes with the host furin. The researchers named this approach FuG1.

FuG1 allows the interruptions of the furin function to limit spike activation, thus specifically limiting the viral transmissibility during its chain of infection in host cells. The , variable-domain-targeting spike in FuG1 is key for furin-targeting specificity to avoid potential toxicity.

Antibody interferes with spike cleavage and stability

The team evaluated the engineered furin disrupter, FuG1, in human lung tissue cells. Tests were run with the original SARS-CoV-2 variant and pseudoviruses. They found that:

  • Adding the furin disruptor peptide did not interfere with the function of the antibody or its ability to bind to the SARS-CoV-2 spike.
  • FuG1 significantly impacted the spike cleavage at furin sites.
  • FuG1 additionally interfered with the overall stability of the SARS-CoV-2 spike , which in general is necessary for infecting cells and transmissibility of the virus.

The next steps for the team will be a series of experiments in mice. They will also test the engineered antibody against current variants like omicron.

Tushir-Singh is cautiously optimistic that variants such as omicron will not yield many differences. "The FuG1 antibody is logical in targeting the newly acquired biological component of SARS-CoV-2 transmissibility—the furin spike cleavage. Since our approach targets the viral assembly process itself, rather than ACE2 neutralization, as long as newly emerging SARS-CoV-2 variants do not interfere with FuG1 antibody binding, it is highly likely this sort of strategy would interfere with viral transmissibility," Tushir-Singh said.

In addition to targeting SARS-CoV-2, Tushir-Singh thinks this approach could be applied to future coronaviruses or any other virus that utilizes proteases like furin to infect  for their pathology.


Explore further

NIH scientists identify mechanism that may influence infectivity of SARS-CoV-2 variants

More information: Tanmoy Mondal et al, A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle, Microbiology Spectrum (2022). DOI: 10.1128/spectrum.02364-21
https://phys.org/news/2022-02-antibody-block-sars-cov-transmission.html

Discovery could enable broad coronavirus vaccine

 The COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the base of its spike protein that is found also on closely related coronaviruses, according to a new study from Scripps Research. The discovery, published Feb 8 in Science Translational Medicine, could inform the design of broad-acting vaccines and antibody therapies capable of stopping future coronavirus pandemics.

The scientists had previously isolated an antibody from a COVID-19 survivor that can neutralize not only SARS-CoV-2 but also several other members of the family of coronaviruses known as beta-coronaviruses. In the new work, they mapped at atomic scale the site, or "epitope," to which the antibody binds on the SARS-Cov-2 spike protein. They showed that the same epitope exists on other beta coronaviruses, and demonstrated with animal models that the antibody is protective against the effects of SARS-CoV-2 infection.

"We're hopeful that the identification of this epitope will help us develop vaccines and  that work against all beta-coronaviruses, including coronaviruses that may jump from animals to humans in the future," says study co-senior author Raiees Andrabi, Ph.D., an institute investigator in the Department of Immunology and Microbiology at Scripps Research.

Beta-coronaviruses have emerged recently as major, ongoing threats to public health. These coronaviruses include SARS-CoV-1, which killed about 800 people, mostly in Asia, in a series of outbreaks in 2002-04; MERS-CoV, which has killed about 900 people, mostly in the Middle East, since 2012; and, of course, SARS-CoV-2, which by now has killed over 5 million people worldwide in the COVID-19 pandemic. Two other beta coronaviruses, HCoV-HKU1 and HCoV-OC43, cause only common colds, but are suspected of having caused deadly pandemics centuries ago, when they first jumped from animals to humans. Researchers widely believe that future coronavirus pandemics initiated by animal-to-human spread are inevitable.

That prospect has spurred efforts towards the development of a pan-beta-coronaviral vaccine or antibody therapy. Scripps researchers took an initial step in that direction in 2020 when they identified an antibody, in a  from a COVID-19 survivor, that could neutralize both SARS-CoV-2 and SARS-CoV-1. Although neutralizing tests weren't available for all other beta-coronaviruses, they found that the antibody at least bound to most of these

In the new study, the team used X-ray crystallography and other techniques to precisely map the antibody's binding site on the SARS-CoV-2 spike protein. They showed that the same site is found on most other beta coronaviruses—which helps explain the antibody's broad effect on these viruses.

"The site is on the stem of the viral spike protein and is part of the 'machinery' the virus uses to fuse with cell membranes in its human or animal hosts after the virus has initially bound to a cell-surface receptor," says study co-senior author Dennis Burton, Ph.D., Chair of the Department of Immunology and Microbiology at Scripps Research. "Fusion allows the viral genetic material to enter and take over host cells, and the crucial role of this machinery explains why the site is consistently present across beta-coronaviruses."

By contrast, the receptor binding site at the top of the viral spike protein mutates relatively rapidly and thus tends to vary greatly from one beta-coronavirus to the next—making it a poor target for broad beta-coronavirus vaccines or antibody therapies.

The researchers now are following up with efforts to find other, perhaps even more broadly effective , in their search for optimal antibodies and vaccines against coronaviruses.


Explore further

Common cold coronaviruses hinder antibody immune response to SARS-CoV-2 infection

More information: Panpan Zhou et al, A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection, Science Translational Medicine (2022). DOI: 10.1126/scitranslmed.abi9215
https://medicalxpress.com/news/2022-02-discovery-enable-broad-coronavirus-vaccine.html

'People's Convoy' Vows Not To Disrupt Super Bowl

The organizers of The People's Convoy released a statement late Thursday that their group "has no intention or plans" to protest the Super Bowl in Los Angeles on Sunday.

"Such notice and rumors are put out there by either another group or paid opposition," Kris Young, one of the administrators for The People's Convoy, posted on the group's Facebook and Telegram accounts late Thursday. 

The People's Convoy Facebook Page

The U.S. Department of Homeland Security had issued a warning that a convoy of truckers protesting against COVID-19 vaccine mandates could impact the Super Bowl, the final game of the season for the National Football League.

The department said a protest similar to ongoing demonstrations in Canada could start in California in the coming days.

Truckers protesting in Canada's capital Ottawa have been blocking main roads, as well as some of the main trade bridges on the U.S.-Canada border.

Instead, Young posted that the People's Convoy will rally on March 4 and 5 in Coachella Valley in Indio, California, before heading to Washington.

However, a separate group called Shut Down the Super Bowl Medical Freedom Protest posted on social media that it plans to start demonstrating against mask mandates beginning at noon on Sunday at SoFi Stadium. 

"Officials will host a Super Bowl while forcing kids to mask," according to the group that states it is part of a "USA Truck Convoy."

As of publication, no additional information about the group or its plans was available.

Some of the initial organizers of The People's Convoy told FreightWaves they backed out of participating in the event after the group's administrators posted on Feb. 8 that "fuel reimbursement upon arrival for all attending the event," which contradicted the group's original message that it wouldn't be accepting donations. 

Gerald Johnson, known as Trucker G, said no one could tell him who was supplying the funds to cover fuel expenses, so he decided to walk away.

"I am all about supporting my brothers and sisters on the road and I'm for freedom but when you can't tell me who I'm getting in bed with or won't supply the names of people I am supposed to trust, it's time for me to bow out and get back to what I know and that's trucking," Trucker G told FreightWaves.

The People's Convoy organizers originally wanted to build on the momentum of Canada's Freedom Convoy, which is entering into its second week to protest vaccine requirements at the U.S.-Canada border.

Some truckers decided not to participate because the group's message about what it hoped to accomplish by convoying cross-country to DC in March wasn't clear since many states have already dropped their mask mandate requirements.

In attendance at the rally in Coachella Valley will be the world's top doctors, "representing the truth about the pandemic and related policies, supportive police, firefighters, military personnel, musicians, inspiring journalists, religious leaders and people from all walks of life," according to The People's Convoy post.

The People's Convoy's first social media page, initially dubbed the "Convoy to D.C. 2022," was removed by Facebook for violating policies around QAnon in early February, according to Fox News. 

https://www.benzinga.com/news/22/02/25558564/peoples-convoy-vows-not-to-disrupt-super-bowl

Goldman Capitulates, Cuts S&P Price Target To 4,900, Warns Of 'Recession Downside' To 3,600

 It was less than three months ago that a gaping divergence emerged on Wall Street between the two most prominent investment banks: in mid-November, Morgan Stanley's Michael Wilson published its 2022 equity market outlook, in which it predicted that the S&P would close the coming year at 4,400, some 6% lower from what was then the current level, as a result of multiple contraction emerging from higher yields and urged clients to exit the US and instead focus on Europe and Japan. So far it has been spot on, with the S&P hitting and then dropping below the bank's year end price target. One day later, taking a far more cheerful approach, Goldman's David Kostin - who like JPM's Marko Kolanovic simply refuses to acknowledge any/all bearish catalyst until they are well in the rearview mirror - published his far more cheerful view on where stock will trade in the coming years, forecasting that the S&P 500 will climb by 9% to 5100 at year-end 2022, "reflecting a prospective total return of 10% including dividends."

While there were pages and pages of gratuitous goalseeked justifications (which nobody would bother to read) for the bank's price target, we wrote that effectively "this entire note boils down to two things: the Fed model, i.e., rates are so low so investors have to buy stocks... and FOMO, or there is nothing else all that money sloshing around can buy."

Fast forward three months later when neither of these is the case, with rates (especially real rates) surging in the past month...

... as the reality of a looming violent, almost Volcker-like rate hiking cycle dawned upon Wall Street...

... derailing any speculation that stocks are now cheap at 20x+ PE multiples based on yields and equity risk premia, and with many markets sliding into either a correction or bear market, one can certainly kiss any FOMO goodbye for the near future. As a result, while bears such as Bank of America and Morgan Stanley are taking victory laps (with both seeing their year-end price targets hit just 3 weeks into the year), Goldman once again found itself in the uncomfortable position of being one of Wall Street's biggest cheerleaders (only JPMorgan is more permabullish) right into a slump.

And so, after weeks of hoping that something would change and stocks would somehow magically resume their trek higher, overnight Goldman's David Kostin finally capitulated, and cuts his year-end S&P forecast from 5,100 to 4,900 - just three months after hiking it from 4,700 to 5,100 because apparently so much has changed since mid-November when the bank published its euphoria year-ahead outlook.

To be sure, Kostin is not too excited to admit that his bearish peers were correct, and start by pointing out the stronger aspects of the market in recent weeks, where stronger-than-expected 4Q earnings results stand out, and which Kostin writes have "helped the S&P 500 find its footing in the last two weeks. S&P 500 EPS grew by 26% year/year in 4Q 2021, 6 pp above the 20% rate that consensus anticipated at the start of earnings season." That said, as Bank of America noted last week, this was already the worst earnings season since Covid emerged, and judging by imploding earnings revisions it's about to get much worse.

That's also why Kostin concedes that despite strong backward-looking 4Q results, "signals for the 2022 earnings outlook have been mixed. 151 companies provided FY1 guidance and 52% guided below consensus." Alongside this, during reporting season, 2022 bottom-up consensus EPS estimates were largely unchanged for the aggregate S&P 500 (+0.5%). And while sales forecasts rose by 0.5% for the typical firm, net margin estimates were unchanged, as companies realize they will no longer be able to pass on rising input costs as easily.

* * *

So looking ahead, Goldman writes that its outlook is a function two things: its EPS forecast and its valuation (i.e., multiple) projection.

Focusing on the first, Kostin still remains upbeat on economic growth - which is the primary driver of the bank's EPS growth forecast - writing that the bank's economists expect real US GDP growth will average 3.2% in 2022 and 2.2% in 2023. Based on the historical link with economic growth alone, this forecast would imply EPS growth of +11% in 2022 and +6% in 2023. However, the bank's estimate of +8% EPS growth in 2022 includes a 4% drag from the Financials sector, which benefited from reserve releases in 2021. And while the bank also forecasts a weakening dollar, a tight labor market, rising oil prices, and elevated inflation (core CPI of 5.3%/2.9% in 2022/23), the bottom line is that its GDP forecast will prove far too high as the US gradually slows into a recession some time in the second half, forcing the Fed to abandon its tightening plans and begin easing. We expect Goldman will figure this out in 3-6 months.

But while Goldman's stubborn insistence that the US economy will continue growing in a time when the Fed hikes 7 times is pleasantly amusing, what is unacceptably unprofessional is its ludicrous insistence that profit margins will not only remain at record highs but continue to expand despite record inflation! Needless to say, this is simply idiotic. Here is a drowning Kostin scrambling to find even the thinnest stick to hold on to:

"The majority of earnings growth in the next two years will come from sales growth, with only limited net profit margin expansion. Our revenue growth forecasts of 10% in 2022 and 6% in 2023 are slightly above consensus, driven by strong nominal GDP growth and a weaker USD. Sales growth, operating leverage, pricing power, and cost management will help margins to rise modestly. We forecast net profit margins will rise by 32 bp to 12.5% in 2022 and by 7 bp to 12.5% in 2023. However, consensus expects margins will expand by 80 bp through 2023." Hilariously, even Kostin admits that "based on history, consensus margin forecasts are typically too optimistic and are eventually reduced, supporting our below-consensus 2023 EPS estimate." Well, here's a thought: maybe fade the optimistic consensus and cut your margin projections. Of course, if that were to happen Goldman would have to issue an outright sell reco on stocks, and the political vampire squid can never do that.

Moving on, and while Goldman index EPS estimates remain unchanged, the bank at least admits that its laughable valuation forecasts make zero sense in a time when the bank is justifying a 2.50% terminal rate, and as Kostin notes, Goldman adjusts its valuation forecast following the bank's revisions to the path of interest rates.

Throwing the bank's economist team under the bus, Kostin writes that "in November, when we published our year-end 2022 target of 5100, our economists expected two Fed hikes in 2022 and a year-end nominal 10-year US Treasury yield of 2%." However, as Kostin then notes, "inflation has been higher than expected" [by Goldman's economists, not by this website] and "Fed policy outlook has changed dramatically (Exhibit 2), and so the bank's economists now expect 7 Fed hikes in 2022, with Goldman's rate strategists "forecasting the nominal 10-year Treasury yield will rise by 33 bp from current level to 2.25%, driven entirely by real yields (+36 bp to -0.15%)." Translation: real rates have peaked and will now tumble as breakevens explode higher, especially if there is an all out conflict between Russia and Ukraine.

Here, Kostin once again exposes his naively permabullish view, writing that he expects that "a narrower equity risk premium (ERP) will offset the impact of higher rates, leaving the cost of equity (COE) and valuations unchanged from current levels." How is this possible? Well, as he explains, he is modeling the ERP as a function of growth expectations, policy uncertainty, consumer confidence, and the size of the Fed balance sheet. By the end of the year, he expects that "policy uncertainty will fall and confidence will rise as investors gain clarity about the path of inflation and Fed policy." Sure, we also may or may not have a world war if Biden keeps pushing his wag the dog agenda but let's ignore that for now.

Putting all this together, Kostin calculates that despite a "modest headwind" from QT, this so-called "clarity" should push the ERP from 5.0% today to 4.6% at year-end, still above the long-term average of 4.3%. Good luck with that "modest headwind" from QT as the Fed's balance sheet shrinks by $2 trillion over the next year.

Kostin then notes that the implied forward P/E multiple at year-end would equal 20x, roughly unchanged from the current level but below our previous forecast of 22x. We'll repeat: Goldman's year end target is going down because the bank is "slashing" its fwd PE multiple from 22 to... 20x! Of course, the real PE multiple heading into a recession should be about 10x, but we are confident that Kostin will advise its clients of this trivial factoid in due course... about 2-4 weeks after the S&P has tumbled another 30%.

At least the Goldman strategist admits that "higher real yields than we forecast would imply downside risk to our valuation estimate." This is useful because just a few weeks ago Goldman's year-end prediction for real rates was -0.70%. They are now -0.40% as the bank which formerly the powerhouse of Wall Street has become its laughing stock with its catastrophic forecasts.

 

In any case, putting it all together, Goldman's revised S&P 500 year-end 2022 price target equals 4900 (-4% from 5100), representing an 11% gain from today, with the bank conceding that "the macro backdrop this year is considerably more challenging than in 2021." However, since it's not a good look for the bank to capitulate so early on what back in November we dubbed a ridiculous projection, the bank continues to - laughably - expect that "equity prices will rise alongside earnings and reach a new all-time high in 2022." Whatever you say, David.

Ironically, the Goldman strategist here comes very close to admitting that his entire analysis is bullshit, writing that "during the last 50 years, a “goldilocks” environment of accelerating GDP growth and stable real yields has typically been associated with a 12-month S&P 500 return of +16%. However, when growth is decelerating and real yields are rising" - like now, for example -  "12-month S&P 500 returns have averaged +8%." 

Now rerun this analysis when inflation is 7.5%. What's that? It shows a collapse in returns? Oh, that's why you ignored the elephant in the room, got it.

Sarcasm aside, Goldman's revised forecast implies a 2022 full-year total return of 4%, modestly below the historical average, while the interim 3-and 6-month targets are 4500 (+2% from today) and 4700 (+6%).

Kostin concludes with the closest thing to a bearish warning we have heard from him ever since he forecast back in March 2020 that the S&P could crash to 2000, which of course bottom-ticked the market. According to the Goldman strategist, "uncertainty abounds regarding the path of inflation and Fed policy. We believe two-sided risks exist to our baseline S&P 500 forecast, but with a larger downside tail."

And so, in addition to his baseline, Kostin considers three alternative scenarios.

  • If inflation remains high and prompts continued Fed hiking that lifts the terminal funds rate well beyond the market and our economists’ estimates, we expect thecost of equity would rise on net and the S&P 500 would decline by 12% to 3900.
  • Alternatively, if inflation recedes by more than expected this year and results in fewer Fed hikes, we expect the cost of equity would fall and the S&P 500 would riseby 24% to 5500.
  • Finally, if the US economy tips into a recession –a question which Goldman's investors have increasingly been asking –the typical 24% recession peak-to-trough price decline would reduce the S&P 500 to 3600.

Spoiler alert: the right scenario will be #3.

https://www.zerohedge.com/markets/goldman-capitulates-cuts-sp-price-target-4900-warns-recession-downside-3600